592 related articles for article (PubMed ID: 26000702)
1. The EGFR/ErbB3 Pathway Acts as a Compensatory Survival Mechanism upon c-Met Inhibition in Human c-Met+ Hepatocellular Carcinoma.
Steinway SN; Dang H; You H; Rountree CB; Ding W
PLoS One; 2015; 10(5):e0128159. PubMed ID: 26000702
[TBL] [Abstract][Full Text] [Related]
2. c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma.
You H; Ding W; Dang H; Jiang Y; Rountree CB
Hepatology; 2011 Sep; 54(3):879-89. PubMed ID: 21618573
[TBL] [Abstract][Full Text] [Related]
3. Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity.
Jo JC; Choi EK; Shin JS; Moon JH; Hong SW; Lee HR; Kim SM; Jung SA; Lee DH; Jung SH; Lee SH; Kim JE; Kim KP; Hong YS; Suh YA; Jang SJ; Choi EK; Lee JS; Jin DH; Kim TW
Mol Cancer Ther; 2015 Nov; 14(11):2613-22. PubMed ID: 26351320
[TBL] [Abstract][Full Text] [Related]
4. Activation of the HGF/c-MET axis promotes lenvatinib resistance in hepatocellular carcinoma cells with high c-MET expression.
Fu R; Jiang S; Li J; Chen H; Zhang X
Med Oncol; 2020 Mar; 37(4):24. PubMed ID: 32166604
[TBL] [Abstract][Full Text] [Related]
5. Down-regulation of c-Met expression inhibits human HCC cells growth and invasion by RNA interference.
Xie B; Xing R; Chen P; Gou Y; Li S; Xiao J; Dong J
J Surg Res; 2010 Aug; 162(2):231-8. PubMed ID: 19765730
[TBL] [Abstract][Full Text] [Related]
6. HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells.
Bachleitner-Hofmann T; Sun MY; Chen CT; Tang L; Song L; Zeng Z; Shah M; Christensen JG; Rosen N; Solit DB; Weiser MR
Mol Cancer Ther; 2008 Nov; 7(11):3499-508. PubMed ID: 18974395
[TBL] [Abstract][Full Text] [Related]
7. miR-1-3p and miR-206 sensitizes HGF-induced gefitinib-resistant human lung cancer cells through inhibition of c-Met signalling and EMT.
Jiao D; Chen J; Li Y; Tang X; Wang J; Xu W; Song J; Li Y; Tao H; Chen Q
J Cell Mol Med; 2018 Jul; 22(7):3526-3536. PubMed ID: 29664235
[TBL] [Abstract][Full Text] [Related]
8. The HGF-MET axis coordinates liver cancer metabolism and autophagy for chemotherapeutic resistance.
Huang X; Gan G; Wang X; Xu T; Xie W
Autophagy; 2019 Jul; 15(7):1258-1279. PubMed ID: 30786811
[TBL] [Abstract][Full Text] [Related]
9. Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells.
Xu H; Stabile LP; Gubish CT; Gooding WE; Grandis JR; Siegfried JM
Clin Cancer Res; 2011 Jul; 17(13):4425-38. PubMed ID: 21622718
[TBL] [Abstract][Full Text] [Related]
10. Chinese herbal formula QHF inhibits hepatocellular carcinoma metastasis via HGF/c-Met signaling pathway.
Yuan S; Gong Y; Chen R; Du J; Zhang H; Chen T
Biomed Pharmacother; 2020 Dec; 132():110867. PubMed ID: 33075668
[TBL] [Abstract][Full Text] [Related]
11. Induction of tumor initiation is dependent on CD44s in c-Met⁺ hepatocellular carcinoma.
Dang H; Steinway SN; Ding W; Rountree CB
BMC Cancer; 2015 Mar; 15():161. PubMed ID: 25886575
[TBL] [Abstract][Full Text] [Related]
12. Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.
Han P; Li H; Jiang X; Zhai B; Tan G; Zhao D; Qiao H; Liu B; Jiang H; Sun X
Mol Oncol; 2017 Mar; 11(3):320-334. PubMed ID: 28164434
[TBL] [Abstract][Full Text] [Related]
13. Elevated hepatocyte growth factor expression as an autocrine c-Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells.
Firtina Karagonlar Z; Koc D; Iscan E; Erdal E; Atabey N
Cancer Sci; 2016 Apr; 107(4):407-16. PubMed ID: 26790028
[TBL] [Abstract][Full Text] [Related]
14. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.
Desbois-Mouthon C; Baron A; Blivet-Van Eggelpoël MJ; Fartoux L; Venot C; Bladt F; Housset C; Rosmorduc O
Clin Cancer Res; 2009 Sep; 15(17):5445-56. PubMed ID: 19706799
[TBL] [Abstract][Full Text] [Related]
15. Preclinical trials for prevention of tumor progression of hepatocellular carcinoma by LZ-8 targeting c-Met dependent and independent pathways.
Wu JR; Hu CT; You RI; Ma PL; Pan SM; Lee MC; Wu WS
PLoS One; 2015; 10(1):e0114495. PubMed ID: 25607934
[TBL] [Abstract][Full Text] [Related]
16. LINC00240 sponges miR-4465 to promote proliferation, migration, and invasion of hepatocellular carcinoma cells via HGF/c-MET signaling pathway.
Bu WJ; Fang Z; Li WL; Wang X; Dong MJ; Tao QY; Zhang L; Xu YQ
Eur Rev Med Pharmacol Sci; 2020 Oct; 24(20):10452-10461. PubMed ID: 33155201
[TBL] [Abstract][Full Text] [Related]
17. Coactivation of receptor tyrosine kinases in malignant mesothelioma as a rationale for combination targeted therapy.
Brevet M; Shimizu S; Bott MJ; Shukla N; Zhou Q; Olshen AB; Rusch V; Ladanyi M
J Thorac Oncol; 2011 May; 6(5):864-74. PubMed ID: 21774103
[TBL] [Abstract][Full Text] [Related]
18. PHA665752, a small-molecule inhibitor of c-Met, inhibits hepatocyte growth factor-stimulated migration and proliferation of c-Met-positive neuroblastoma cells.
Crosswell HE; Dasgupta A; Alvarado CS; Watt T; Christensen JG; De P; Durden DL; Findley HW
BMC Cancer; 2009 Nov; 9():411. PubMed ID: 19939254
[TBL] [Abstract][Full Text] [Related]
19. HGF/c-MET pathway contributes to cisplatin-mediated PD-L1 expression in hepatocellular carcinoma.
Zhang ZS; Yang RH; Yao X; Cheng YY; Shi HX; Yao CY; Gao ZX; Qi DF; Zhang WK; Dou YY; Guo J; Hu MW; Zhao H; Fang D
Cell Biol Int; 2021 Dec; 45(12):2521-2533. PubMed ID: 34486197
[TBL] [Abstract][Full Text] [Related]
20. Prostaglandin E2 receptor EP1 transactivates EGFR/MET receptor tyrosine kinases and enhances invasiveness in human hepatocellular carcinoma cells.
Han C; Michalopoulos GK; Wu T
J Cell Physiol; 2006 Apr; 207(1):261-70. PubMed ID: 16331686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
